Want to see JP:7079 full AI Analyst Report?
Top Page
WDB coco Co., Ltd.
(7079)
Select Model
Select Model
Rating:80Outperform
Price Target:
¥2,990.00
▲(10.37% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by strong financial fundamentals (especially a very low-debt balance sheet and healthy margins) and exceptionally attractive valuation (very low P/E with a ~3.65% dividend yield). Offsetting these positives, technical signals are largely neutral and financial momentum weakened in FY2026 (revenue and cash generation stepped down), which tempers the overall rating.
Positive Factors
Very Low Leverage
The extremely low debt burden reduces financial risk and interest pressure, while giving the company flexibility to withstand weaker demand, fund operations, and potentially invest without relying heavily on external financing.
Negative Factors
Revenue Contraction
The recent revenue decline signals weaker demand, customer activity, or business mix and could pressure future operating leverage. Sustained top-line contraction would make it harder to preserve margins and maintain the company’s earnings base.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
The extremely low debt burden reduces financial risk and interest pressure, while giving the company flexibility to withstand weaker demand, fund operations, and potentially invest without relying heavily on external financing.
Read all positive factors
WDB coco Co., Ltd. (7079) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.25B
Dividend Yield3.67%
Average Volume (3M)4.28K
Price to Earnings (P/E)0.9
Beta (1Y)0.16
Revenue Growth-11.16%
EPS Growth-21.80%
CountryJP
Employees516
SectorHealthcare
Sector Strength45
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)282.47
Shares Outstanding2,405,000
10 Day Avg. Volume5,990
30 Day Avg. Volume4,283
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)1.30
Price to Sales (P/S)1.30
P/FCF Ratio11.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)457.4
Revenue Forecast (FY)¥6.10B
WDB coco Co., Ltd. Business Overview & Revenue Model
Company Description
WDB coco Co., Ltd. offers specialized contractual services to pharmaceutical companies throughout Japan. The firm plays a crucial role in advancing pharmaceuticals and medical devices, with a particular focus on safety information management, supp...
How the Company Makes Money
null...
WDB coco Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
74
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.82B | 5.33B | 4.60B | 4.07B | 3.62B |
| Gross Profit | 1.71B | 2.07B | 1.93B | 1.58B | 1.44B |
| EBITDA | 1.01B | 1.36B | 1.31B | 1.12B | 981.71M |
| Net Income | 679.31M | 912.90M | 857.83M | 743.63M | 647.70M |
Balance Sheet | |||||
| Total Assets | 5.70B | 5.60B | 4.67B | 3.67B | 3.14B |
| Cash, Cash Equivalents and Short-Term Investments | 3.76B | 3.48B | 2.66B | 2.00B | 1.89B |
| Total Debt | 80.41M | 29.81M | 27.12M | 24.32M | 33.52M |
| Total Liabilities | 921.26M | 1.30B | 1.10B | 866.02M | 994.57M |
| Stockholders Equity | 4.78B | 4.30B | 3.56B | 2.80B | 2.15B |
Cash Flow | |||||
| Free Cash Flow | 521.82M | 1.10B | 753.84M | 469.46M | 719.72M |
| Operating Cash Flow | 570.54M | 1.10B | 772.20M | 517.49M | 747.90M |
| Investing Cash Flow | -80.53M | -88.33M | -91.82M | -302.97M | -60.48M |
| Financing Cash Flow | -207.03M | -195.83M | -110.94M | -101.21M | -79.11M |
WDB coco Co., Ltd. Technical Analysis
Positive
2709.00
Price Trends
2582.70
Positive
2588.68
Positive
2590.44
Positive
Market Momentum
-2.11
Positive
52.24
Neutral
27.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7079, the sentiment is Positive. The current price of 2709 is above the 20-day moving average (MA) of 2592.25, above the 50-day MA of 2582.70, and above the 200-day MA of 2590.44, indicating a bullish trend. The MACD of -2.11 indicates Positive momentum. The RSI at 52.24 is Neutral, neither overbought nor oversold. The STOCH value of 27.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7079.
WDB coco Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥6.25B | 0.95 | ― | 3.00% | -11.16% | -21.80% | |
54 Neutral | ¥5.68B | -45.84 | ― | 3.21% | 0.60% | -131.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | ¥4.47B | -4.71 | ― | ― | 167.44% | 49.38% | |
44 Neutral | ¥5.75B | -7.00 | ― | ― | 364.72% | 18.43% | |
41 Neutral | ¥3.44B | -1.37 | ― | ― | ― | -5.66% | |
40 Neutral | ¥4.97B | -0.63 | ― | ― | -37.69% | 1.85% |
* Healthcare Sector Average
JP:7079
WDB coco Co., Ltd.
2,587.00
-88.03
-3.29%
JP:4539
Nippon Chemiphar Co., Ltd.
1,574.00
3.84
0.24%
JP:4582
Symbio Pharmaceuticals Limited
63.00
-85.00
-57.43%
JP:4586
Medrx Co., Ltd.
67.00
-44.00
-39.64%
JP:4883
Modalis Therapeutics Corporation
33.00
-54.00
-62.07%
JP:4892
Cyfuse Biomedical K.K.
570.00
-52.00
-8.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.